Abbvie Inc

NYSE:ABBV   3:59:58 PM EDT
132.95
-2.26 (-1.67%)
: $132.75 -0.20 (-0.15%)
Strategic Combinations, Regulatory, Earnings Announcements

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

Published: 12/10/2021 11:41 GMT
Abbvie Inc (ABBV) - Springworks Therapeutics Announces Clinical Collaboration With Abbvie to Evaluate Nirogacestat in Combination With Abbv-383 in Patients With Relapsed Or Refractory Multiple Myeloma.
Springworks Therapeutics - Under Agreement, Abbvie Will Sponsor and Conduct Phase 1b Study and Will Assume All Costs Associated With Study.
Springworks Therapeutics - Abbvie, Co to Form Joint Steering Committee to Manage Clinical Study, Which is Expected to Commence in H1 of 2022.
Revenue is expected to be $14.94 Billion
Adjusted EPS is expected to be $3.28

Next Quarter Revenue Guidance is expected to be $13.86 Billion
Next Quarter EPS Guidance is expected to be $3.21

More details on our Analysts Page.